BFRI · Biofrontera Inc.
$1.42
+0.07 (+5.19%)
At close · Aug 18
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$19.31M
Shares
14.85M
Biofrontera Inc. Earnings Call Transcripts
Every quarterly earnings call for Biofrontera Inc. (BFRI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.3%
$4.32M
−$2.57M
'22 Q3
22-11-14
▲10.7%
$10.14M
−$2.79M
'22 Q4
23-03-08
▼10.4%
$8.73M
−$7.48M
'23 Q1
23-05-12
▲31.2%
$5.85M
−$9.84M
'23 Q2
23-08-11
▲105.8%
$8.90M
−$6.34M
'23 Q3
23-11-09
▲4.4%
$10.59M
$3.53M
'23 Q4
24-01-11
▼9.4%
$7.91M
−$10.44M
'24 Q1
24-05-15
▲34%
$7.84M
−$257,000
'24 Q2
24-08-14
▲1.3%
$9.01M
−$5.67M
'24 Q3
24-11-13
▲18.5%
$12.56M
−$1.40M
'24 Q4
25-03-21
▲8.5%
$8.59M
−$4.20M
'25 Q1
25-05-15
▲15.2%
$9.03M
−$5.32M
'25 Q2
25-08-13
▼22.5%
$6.99M
−$6.65M
'25 Q3
25-11-13
▲36.2%
$17.10M
$5.64M
'25 Q4
26-03-19
▲17.4%
$10.08M
−$4.75M
'26 Q1
26-05-14
LATEST
▲32.9%
$12.00M
−$604,000
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Biofrontera Inc. Q2 FY2026 Earnings Call
Revenue
$12.00M
▲ 32.9% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Biofrontera Inc. Q1 FY2026 Earnings Call
Confident tone
Business transformation and cost structure
Pipeline and clinical development
AK label expansion
Revenue
$10.08M
▲ 17.4% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Biofrontera Inc. Q4 FY2025 Earnings Call
Confident tone
Loss reduction and path to breakeven
Clinical pipeline and regulatory milestones
Strategic transaction with Biofrontera AG
Revenue
$17.10M*
▲ 36.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Biofrontera Inc. Q3 FY2025 Earnings Call
Revenue
$6.99M
▼ 22.5% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Biofrontera Inc. Q2 FY2025 Earnings Call
Confident tone
Record H1 2025 sales results
Restructuring of Biofrontera AG relationship
Acne vulgaris Phase II trial
Revenue
$9.03M
▲ 15.2% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Biofrontera Inc. Q1 FY2025 Earnings Call
Confident tone
Ameluz formulation patent
Label extension clinical trials
Acne indication (Phase II)
Revenue
$8.59M
▲ 8.5% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Biofrontera Inc. Q4 FY2024 Earnings Call
Revenue
$12.56M*
▲ 18.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Biofrontera Inc. Q3 FY2024 Earnings Call
Confident tone
RhodoLED XL lamp launch
Revenue growth and Hurricane Milton impact
Clinical trial progress in new indications
Revenue
$9.01M
▲ 1.3% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Biofrontera Inc. Q2 FY2024 Earnings Call
Confident tone
Revenue growth and quarterly sales performance
Clinical trials and pipeline expansion
Balance sheet and debt repayment
Revenue
$7.84M
▲ 34% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Biofrontera Inc. Q1 FY2024 Earnings Call
Confident tone
Ameluz license and supply agreement renegotiation
Clinical trials and FDA submissions
Change Healthcare cyberattack impact on Q1 revenue
Revenue
$7.91M
▼ 9.4% YoY Diluted EPS
$-2.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-11
Biofrontera Inc. Q4 FY2023 Earnings Call
Confident tone
Ameluz and PDT product strategy
Product launches and patents
Financing and balance sheet
Revenue
$10.59M*
▲ 4.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Biofrontera Inc. Q3 FY2023 Earnings Call
Revenue
$8.90M
▲ 105.8% YoY Diluted EPS
$-4.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Biofrontera Inc. Q2 FY2023 Earnings Call
Revenue
$5.85M
▲ 31.2% YoY Diluted EPS
$-7.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Biofrontera Inc. Q1 FY2023 Earnings Call
Revenue
$8.73M
▼ 10.4% YoY Diluted EPS
$-5.60
▼ 187.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
Biofrontera Inc. Q4 FY2022 Earnings Call
Revenue
$10.14M*
▲ 10.7% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Biofrontera Inc. Q3 FY2022 Earnings Call
Revenue
$4.32M
▼ 0.3% YoY Diluted EPS
$-2.26
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
Biofrontera Inc. Q2 FY2022 Earnings Call
Revenue
$4.46M
▼ 23.9% YoY Diluted EPS
$-0.90
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-08
Biofrontera Inc. Q1 FY2022 Earnings Call
Revenue
$9.75M
▲ 105.5% YoY Diluted EPS
$6.40
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-18
Biofrontera Inc. Q4 FY2021 Earnings Call
Revenue
$9.17M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-30
Biofrontera Inc. Q3 FY2021 Earnings Call
Revenue
$4.33M
▲ 33.3% YoY Diluted EPS
$-40.00
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts
CIK
1858685
CUSIP
09077D209
13F (30d)
24 filings
23 filers
Visit website
Investor relations